HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enforma settlement

This article was originally published in The Tan Sheet

Executive Summary

Infomercial producer Modern Interactive Technology has settled FTC charges alleging the firm played an "active role" in writing, editing and producing infomercials for the Enforma System of weight-loss products, the commission announces March 1. The company and principals Mark Levine and David Richmond originally were charged in August 2000, shortly after Enforma Natural Products was charged with making unsubstantiated ad claims for Fat Trapper and Exercise in a Bottle, which comprise the system. The settlement prohibits the firm from "misrepresenting the profession, expertise, training, education, experience, or qualifications of any person who advertises, promotes, or endorses any product, service or program." Enforma Natural Products also recently settled FTC charges in an agreement that bars the company from future marketing of weight-loss products (1"The Tan Sheet" Jan. 24, 2005, p. 12)...

You may also be interested in...



Weight-Loss Product Manufacturers Receive FTC Rebuke

A Federal Trade Commission settlement with the makers of Exercise in a Bottle and Fat Trapper barring the firms from marketing weight-loss products in the future is an example of the agency's willingness to deliver severe punishments against repeat offenders

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.

Day One Springs Into Commercial Action With Ojemda Approval

The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126729

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel